- Home
- PRAX vs SABR Comparison
PRAX vs SABR Comparison
Compare PRAX & SABR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAX
- SABR
- Stock Information
- Founded
- PRAX 2015
- SABR 2006
- Country
- PRAX United States
- SABR United States
- Employees
- PRAX N/A
- SABR N/A
- Industry
- PRAX Biotechnology: Pharmaceutical Preparations
- SABR Computer Software: Programming Data Processing
- Sector
- PRAX Health Care
- SABR Technology
- Exchange
- PRAX Nasdaq
- SABR Nasdaq
- Market Cap
- PRAX 1.4B
- SABR 1.3B
- IPO Year
- PRAX 2020
- SABR 2014
- Fundamental
- Price
- PRAX $74.49
- SABR $4.52
- Analyst Decision
- PRAX Strong Buy
- SABR Hold
- Analyst Count
- PRAX 9
- SABR 4
- Target Price
- PRAX $149.00
- SABR $3.25
- AVG Volume (30 Days)
- PRAX 388.8K
- SABR 4.0M
- Earning Date
- PRAX 03-04-2025
- SABR 02-20-2025
- Dividend Yield
- PRAX N/A
- SABR N/A
- EPS Growth
- PRAX N/A
- SABR N/A
- EPS
- PRAX N/A
- SABR N/A
- Revenue
- PRAX $1,605,000.00
- SABR $3,029,565,000.00
- Revenue This Year
- PRAX N/A
- SABR $6.34
- Revenue Next Year
- PRAX N/A
- SABR $5.08
- P/E Ratio
- PRAX N/A
- SABR N/A
- Revenue Growth
- PRAX N/A
- SABR 4.19
- 52 Week Low
- PRAX $33.01
- SABR $1.81
- 52 Week High
- PRAX $91.83
- SABR $4.63
- Technical
- Relative Strength Index (RSI)
- PRAX 42.80
- SABR 78.07
- Support Level
- PRAX $76.00
- SABR $3.39
- Resistance Level
- PRAX $91.83
- SABR $3.60
- Average True Range (ATR)
- PRAX 6.29
- SABR 0.19
- MACD
- PRAX -1.10
- SABR 0.10
- Stochastic Oscillator
- PRAX 2.42
- SABR 92.25
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.
About SABR Sabre Corporation
Sabre holds the number-two air booking volume share in the global distribution system industry. The travel solutions segment represented 91% of total 2023 revenue, split between distribution (78% of segment sales) and airline IT solutions (22%) revenue. The company also has a growing hotel IT solutions division (9% of revenue). Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.